231 related articles for article (PubMed ID: 33616448)
1. Increased Efficiency for Biallelic Mutations of the
Lin D; Scheller SH; Robinson MM; Izadpanah R; Alt EU; Braun SE
CRISPR J; 2021 Feb; 4(1):92-103. PubMed ID: 33616448
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
[TBL] [Abstract][Full Text] [Related]
3. CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection.
Wang W; Ye C; Liu J; Zhang D; Kimata JT; Zhou P
PLoS One; 2014; 9(12):e115987. PubMed ID: 25541967
[TBL] [Abstract][Full Text] [Related]
4. Biallelic, Selectable, Knock-in Targeting of CCR5
Scheller SH; Rashad Y; Saleh FM; Willingham KA; Reilich A; Lin D; Izadpanah R; Alt EU; Braun SE
Front Immunol; 2022; 13():821190. PubMed ID: 35386712
[TBL] [Abstract][Full Text] [Related]
5. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
[TBL] [Abstract][Full Text] [Related]
8. Host Double Strand Break Repair Generates HIV-1 Strains Resistant to CRISPR/Cas9.
Yoder KE; Bundschuh R
Sci Rep; 2016 Jul; 6():29530. PubMed ID: 27404981
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Cas9 by viral proteins Tat and Rev for HIV-1 inactivation.
Vergara-Mendoza M; Gomez-Quiroz LE; Miranda-Labra RU; Fuentes-Romero LL; Romero-Rodríguez DP; González-Ruiz J; Hernández-Rizo S; Viveros-Rogel M
Antiviral Res; 2020 Aug; 180():104856. PubMed ID: 32579898
[TBL] [Abstract][Full Text] [Related]
11. Lentivirus pre-packed with Cas9 protein for safer gene editing.
Choi JG; Dang Y; Abraham S; Ma H; Zhang J; Guo H; Cai Y; Mikkelsen JG; Wu H; Shankar P; Manjunath N
Gene Ther; 2016 Jul; 23(7):627-33. PubMed ID: 27052803
[TBL] [Abstract][Full Text] [Related]
12. A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape.
Lebbink RJ; de Jong DC; Wolters F; Kruse EM; van Ham PM; Wiertz EJ; Nijhuis M
Sci Rep; 2017 Feb; 7():41968. PubMed ID: 28176813
[TBL] [Abstract][Full Text] [Related]
13. Improved Cas9 activity by specific modifications of the tracrRNA.
Scott T; Urak R; Soemardy C; Morris KV
Sci Rep; 2019 Nov; 9(1):16104. PubMed ID: 31695072
[TBL] [Abstract][Full Text] [Related]
14. Antiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure.
Khan A; Paneerselvam N; Lawson BR
Clin Immunol; 2023 Oct; 255():109741. PubMed ID: 37611838
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Employs Multiple Mechanisms To Resist Cas9/Single Guide RNA Targeting the Viral Primer Binding Site.
Wang Z; Wang W; Cui YC; Pan Q; Zhu W; Gendron P; Guo F; Cen S; Witcher M; Liang C
J Virol; 2018 Oct; 92(20):. PubMed ID: 30068653
[TBL] [Abstract][Full Text] [Related]
17. PlmCas12e (CasX2) cleavage of CCR5: impact of guide RNA spacer length and PAM sequence on cleavage activity.
Armstrong DA; Hudson TR; Hodge CA; Hampton TH; Howell AL; Hayden MS
RNA Biol; 2023 Jan; 20(1):296-305. PubMed ID: 37287312
[TBL] [Abstract][Full Text] [Related]
18. sgRNA Sequence Motifs Blocking Efficient CRISPR/Cas9-Mediated Gene Editing.
Graf R; Li X; Chu VT; Rajewsky K
Cell Rep; 2019 Jan; 26(5):1098-1103.e3. PubMed ID: 30699341
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.
Herskovitz J; Hasan M; Patel M; Blomberg WR; Cohen JD; Machhi J; Shahjin F; Mosley RL; McMillan J; Kevadiya BD; Gendelman HE
EBioMedicine; 2021 Nov; 73():103678. PubMed ID: 34774454
[TBL] [Abstract][Full Text] [Related]
20. Design and Evaluation of Guide RNA Transcripts with a 3'-Terminal HDV Ribozyme to Enhance CRISPR-Based Gene Inactivation.
Berkhout B; Gao Z; Herrera-Carrillo E
Methods Mol Biol; 2021; 2167():205-224. PubMed ID: 32712922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
